LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

PCR-Based SARS-CoV-2 Assay Quickly Detects All Known COVID-19 Variants

By LabMedica International staff writers
Posted on 17 Feb 2022
Image: Rapid Screening Test for all SARS-CoV-2 Variants (Photo courtesy of Unsplash)
Image: Rapid Screening Test for all SARS-CoV-2 Variants (Photo courtesy of Unsplash)

A rapid test that detects all known COVID-19 variants, including the highly transmissible Omicron variant, is up for approval for clinical testing, and could guide treatment as well as identify high-risk patients.

The test, which has been developed by researchers at Rutgers New Jersey Medical School (Newark, NJ, USA) and can be performed at laboratories experienced in COVID-19 testing, can quickly detect clinical samples that contain the SARS-CoV-2 virus with signature mutations for each known variant of concern - namely, the Alpha, Beta/Gamma, Delta and Omicron variants. The test uses special probes called “sloppy molecular beacons” that perform particularly well at detecting mutations in organisms that mutate frequently. These probes work even if other mutations unexpectedly develop near a mutation of interest. A study demonstrated that their approach is 100% sensitive and specific for identifying the correct variant when tested on clinical samples. The test can be used in a variety of instruments and assay formats.

The researchers are now working to obtain rapid approval to use the new test on patients, where it could help determine the correct type of antibody therapy and potentially help identify patients at high risk for severe COVID-19. To bolster the world’s public health fight against COVID-19, the team is releasing all of the information needed to create and run the test as well as supporting information.

“Our approach is unusually flexible in being able to detect unanticipated mutations,” said David Alland, director of the Rutgers New Jersey Medical School Public Health Research Institute and the Center for COVID-19 Response and Pandemic Preparedness. “We had recently improved an older version of the assay, so that it could detect the Delta variant, but when Omicron appeared, we suspected that it would be able to specifically identify this variant as well, and we are happy to find that our testing shows that we were correct.”

Related Links:
Rutgers New Jersey Medical School

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
8-Channel Pipette
SAPPHIRE 20–300 µL

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more